Newro Foundation research team, Prof David Walker, Neurosurgeon and Beth Morrison, Clinical Research & Development Manager, have been working in collaboration with the School of Medicine, QIMR and the Department of Pathology, Hong Kong to research the impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy.
Clinical response to antibody-based immunotherapies targeting checkpoint inhibitors is critically dependent on the tumor immune microenvironment (TIME). However, the precise impact of the TIME on adoptive cellular immunotherapy remains unexplored. Here we have conducted a long-term follow-up analysis of patients with recurrent glioblastoma multiforme (GBM) who were treated with autologous CMV-specific T-cell therapy to delineate the potential impact of the TIME on their clinical response.
The case study has been published by the Australian and New Zealand Society for Immunology Inc. Read the full case study here.